

Advance-HTA Capacity Building Workshop

25-26 September 2014

Hotel Mercure Warszawa Grand

28 Krucza Street, 00-522 Warsaw, Poland

Agenda

Day I - Thursday 25 September

- 13:30-13:45 Registration
- 13:45-14:00 Welcome and Introduction to Advance-HTA, **Wojciech Matuszewicz (AOTM)**
- 14:00-15:25 **Session 1: Introduction to Health Technology Assessment**
- HTA: Models, Costs and Benefits, **John Cairns (LSHTM)** 14:00-14:30
 - Processes and Evidence Requirements, **Panos Kanavos (LSE)** 14:30-14:50
 - HTA and the Patient, **Jean Mossman (EBC)** 14:50-15:10
- Q&A 15:10-15:25
- 15:25-15:40 *Coffee Break*
- 15:40-17:20 **Session 2: HTA Experiences in South and East Europe and Lessons Learned**
- Survey Results in South and East Europe, **Jaime Espin (EASP)** 15:40-16:00
 - HTA in Poland: the process of adoption and current application, **Anna Zawada (AOTM)** 16:00-16:15
 - The experiences of GYEMSZI TEI - the Hungarian HTA office, **Bertalan Nemeth (GYEMSZI)** 16:15-16:30
 - HTA in Croatia: First Five Years, **Mirjana Huic (AAZ)** 16:30-16:45
 - Lessons Learned and Way Forward, **Jaime Espin (EASP)** 16:45-17:05
- Q&A 17:05-17:20
- 17:20-17:30 Summary and End of Day I, **Panos Kanavos (LSE)**
- 19:00-20:30 **Warsaw City Tour**
- 20:30 **Evening Social Event**

Day II: Friday 26 September

08:30-08:40 Welcome, **Anna Zawada (AOTM)**

08:40-10:30 **Session 1: Critical issues in appraisal of medical technology**

- Value for money, **John Cairns (LSHTM)** 8:40-9:00
- Value assessment methods and application of Multiple Criteria Decision Analysis for HTA, **Panos Kanavos and Aris Angelis (LSE)** 9:00-9:30
- Methods of preference elicitation (EQ5D and measures of utility), **Valentina Prevolnik-Rupel (IER)** 09:30-09:50
- Willingness to pay thresholds and their use, **Sofie Larsson (TLV)** 09:50-10:10
- Q&A 10:10- 10:30

10:30-10:40 *Coffee Break*

10:40-12:00 **Session 2: HTA in Context: Medical Devices and Orphan Drugs**

- Medical Devices: Taxonomy, special considerations and best practice case studies, **Reinhard Busse (TUB)** 10:40-11:10
- Orphan Drugs: Special Considerations, **Elena Nicod (LSE)** 11:10-11:30
- Networks for rare diseases, **Domenica Taruscio (ISS)** 11:30-11:45
- Q&A 11:45-12:00

12:00-13:00 *Lunch*

13:00-14:15 **Session 3: Empirical evidence on use of HTA**

- The NICE experience, **Francis Ruiz (NICE Int.)** 13:00-13:20
- BURQOL, **Julio Lopez Bastida (UCLM)** 13:20-13:40
- HTA in practice: case studies across countries, **Elena Nicod (LSE)** 13:40-14:00
- Q&A 14:00-14:15

14:15-14:30 *Coffee Break*

14:30-15:50 **Session 4: The Way Forward**

- | | |
|---|-------------|
| - EUnetHTA Core model , Finn Borlum Kristensen (EUnetHTA) | 14:30-14:50 |
| - Risk sharing agreements, Panos Kanavos (LSE) | 14:50-15:10 |
| - Risk sharing agreements: the case of Sweden, Sofie Larsson (TLV) | 15:10-15:30 |
| Q&A | 15:30-15:50 |

15:50-16:00 Summary and Next Steps, **Panos Kanavos (LSE)**